- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02767804
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina
- Cemic
-
Caba, Argentina
- Fundacion Favaloro
-
Pergamino, Argentina
- Centro de Investigacion Pergamino SA
-
Rosario, Argentina
- Sanatorio Parque S.A.
-
-
-
-
-
Camperdown, Australia
- Chris O Brien Lifehouse
-
Woolloongabba, Australia
- Princess Alexandra Hospital
-
-
New South Wales
-
Albury, New South Wales, Australia, 2640
- Border Medical Oncology Research Unit
-
Camperdown, New South Wales, Australia
- Chris O'Brien Lifehouse
-
-
Queensland
-
Woolloongabba, Queensland, Australia
- Princess Alexandra Hospital
-
-
-
-
-
Brussels, Belgium, 1090
- UZ Brussel
-
Yvoir, Belgium, 5530
- CHU UCL Namur
-
-
-
-
-
Fortaleza, Brazil, 60351-010
- Hospital Haroldo Juacaba - Instituto do Cancer do Ceara
-
Salvador, Brazil, 40170-110
- Nucleo de Oncologia da Bahia - NOB
-
Santo André, Brazil, 09060-650
- Fundacao do ABC Faculdade de Medicina do ABC
-
São Paulo, Brazil, 01321
- Hospital Paulistano
-
-
SP
-
São Paulo, SP, Brazil, 01246-000
- Instituto do Cancer do Estado de Sao Paulo
-
São Paulo, SP, Brazil, 14784-400
- Hospital de Cancer de Barretos - Fundacao Pio XII
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
Quebec
-
Quebec City, Quebec, Canada, G1V 4G5
- Infirmière recherche Clinique, IUCPQ
-
-
-
-
-
Beijing, China, 100142
- Beijing Cancer Hospital
-
Beijing, China
- Beijing Cancer Hospital
-
Beijing, China, 100142
- Peking university cancer hospital
-
Hangzhou, China
- ZheJiang Cancer Hospital
-
Hangzhou, China
- The First Affiliated Hospital, Zhejiang University
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Anhui Provincial Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100032
- Peking Union Medical College Hospital
-
Beijing, Beijing, China, 100020
- Beijing Chao Yang Hospital
-
Beijing, Beijing, China, 100142
- Peking university cancer hospital
-
Beijing, Beijing, China, 101149
- Beijing Chest Hospital,Capital Medical University
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Fujian Provincial Cancer Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Guangdong General Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050011
- Fourth Hospital of Hebei Medical University
-
-
Hubei
-
Wuhan, Hubei, China, 430079
- Hubei Cancer Hospital
-
Wuhan, Hubei, China, 430030
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
-
Wuhan, Hubei, China, 420104
- Union Hospital of Tongji Medical College of Huazhong Science and Techology University
-
-
Hunan
-
Changsha, Hunan, China, 410006
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210002
- Nanjing General Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- The Second Affiliated Hospital of Nanchang University
-
-
Jilin
-
Changchun, Jilin, China, 130000
- The First Bethune Hospital of Jilin University
-
Changchun, Jilin, China, 130012
- Jilin Cancer Hospital
-
-
Liaoning
-
Shenyang, Liaoning, China, 110001
- The First Hospital of China Medical University
-
-
Shandong
-
Qingdao, Shandong, China, 266071
- The Affiliated Hospital of Qingdao University
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Shanghai Chest Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital, Sichuan University
-
-
Tianjin
-
Tianjin, Tianjin, China, 300052
- Tianjin Medical University General Hospital Mailing No.154 Anshan Avenue Heping District
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- ZheJiang Cancer Hospital
-
-
-
-
-
Ostrava-Vitkovice, Czechia, 70384
- Vítkovická Nemocnice , a.s.
-
Plesice, Czechia, 26204
- Nemocnice Na Plesi s.r.o.
-
Usti nad Labem, Czechia, 40113
- Krajská zdravotní, a.s., Masarykova nemocnice
-
-
-
-
-
Brest, France, 29200
- Hôpital Morvan CHRU de Brest
-
Dijon, France, 21000
- Centre GF Leclerc
-
Lille, France, 59000
- CHRU Lille
-
Montpellier, France, 34298
- ICM Val D'Aurelle
-
Paris, France, 75010
- Hôpital Saint-Louis
-
Rennes, France, 35033
- CHU de Rennes Hopital Pontchaillou
-
Saint Herblain, France, 44805
- Institut de cancerologie de l'ouest (ICO)
-
Strasbourg, France, 67091
- Nouvel Hospital Civil de Stasbourg
-
-
-
-
-
Berlin, Germany, 13353
- Klinik m. S. Infektiologie & Pneumologie
-
Berlin, Germany, D-12351
- Vivantes Klinikum Neukölln
-
Grosshansdorf, Germany, 22927
- Lungen Clinic Grosshansdorf
-
Lowenstein, Germany, 74245
- Klinik Löwenstein gGmbH Med. Klinik II Onkologie
-
Stolberg, Germany, D-52222
- Praxis Hämatologie und Onkologie Stolberg
-
-
-
-
-
Hong Kong, Hong Kong
- Queen Elizabeth Hospital
-
Hong Kong, Hong Kong
- The University of Hong Kong, Queen Mary Hospital
-
Hong Kong, Hong Kong
- The University of Hong Kong/Queen Mary Hospital
-
Sha Tin, Hong Kong
- Prince of Wales Hospital
-
-
-
-
-
Be'er Sheva', Israel, 84101
- Soroka Medical Centre
-
Haifa, Israel, 31096
- Rambam Health Care Campus/ Oncology Institute
-
Jerusalem, Israel, 9112001
- Hadassah Medical Center
-
Petah Tiqva, Israel, 49100
- Rabin Medical Center Institute of Oncology, Davidoff Center
-
Ramat Gan, Israel, 5262000
- Chaim Sheba Medical Center
-
-
-
-
-
Aviano, Italy, 33081
- Centro Riferimento Oncologico CRO Aviano
-
Legnago, Italy, 37045
- Ospedale Mater Salutis
-
Meldola, Italy, 47014
- IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
-
Milano, Italy, 20141
- Ieo Istituto Europeo Di Oncologia
-
Napoli, Italy, 80131
- AOU Federico II, Oncologia Medica
-
Perugia, Italy, 06132
- Centro Operativo Studi Clinici S.C.Oncologia Medica
-
Ravenna, Italy, 48121
- UOC Oncologia Medica
-
Rozzano, Italy, 20089
- Istituto Clinico Humanitas IRCCS
-
Sondrio, Italy, 20121
- Azienda Socio Sanitaria Territoriale (ASST) della Valtellina e dell'Alto Laria
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
-
-
-
-
Amsterdam, Netherlands, 1007 MB
- VU Medical Center
-
Maastricht, Netherlands, 6229HX
- Maastricht University Medical Centre (MUMC)
-
-
-
-
-
Lima, Peru
- Clinica Ricardo Palma
-
-
-
-
-
Gdańsk, Poland
- Medical University of Gdansk
-
Warsaw, Poland
- Centrum Onkologii-Instytut im. M. Sklodowskiej Curie
-
-
-
-
-
Moscow, Russian Federation, 115478
- Federal State Budgetary Scientific Institution Russian Oncological Scientific Center named after N.N. Blokhin
-
Moscow, Russian Federation, 121309
- LLC "VitaMed"
-
Moscow, Russian Federation, 143423
- State Budgetary Institution of Healthcare of the city of Moscow "MOSCOW CITY ONCOLOGY HOSPITAL # 62"
-
Omsk, Russian Federation
- BHI of Omsk region "Clinical oncology dispensary"
-
Saint Petersburg, Russian Federation, 197022
- Pavlov First Medical University
-
Saint Petersburg, Russian Federation
- FBI "Scientific Research Institute of Oncology n. a. N. N. Petrov"
-
-
-
-
-
Badajoz, Spain, 06080
- Hospital Universitario Infanta Cristina
-
Barcelona, Spain, 08003
- Hospital del Mar
-
Barcelona, Spain, 08035
- Hospital Vall d'Hebron
-
Barcelona, Spain, 08025
- Hospital de la Santa Creu i Sant Pau
-
Barcelona, Spain, 08028
- Hospital Universitario Quiron Dexeus
-
Barcelona, Spain, 08208
- Hospital Parc Tauli'
-
Girona, Spain, 17007
- ICO Girona - Hospital Doctor Josep Trueta
-
Madrid, Spain
- Hospital General Universitario Gregorio Marañon
-
Palma de Mallorca, Spain, 07198
- Hospital Son Ltatzer
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Clinica Universidad de Navarra
-
-
-
-
-
Edirne, Turkey, 22030
- Trakya University Balkan Oncology Hospital
-
Istanbul, Turkey, 34098
- Istanbul University Cerrahpasa Medical Faculty
-
Izmir, Turkey, 35100
- Ege University Medical Faculty
-
-
-
-
-
Blackwood, United Kingdom, FY3 8NR
- Blackpool Victoria Hospital
-
Bristol, United Kingdom, BS10 5NB
- Southmead Hospital
-
Nottingham, United Kingdom, NG17 4JL
- Kings Mill Hospital
-
Wirral, United Kingdom, CH63 4JY
- The Clatterbridge Cancer Centre NHS Foundation Trust
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic
-
-
Florida
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Athens, Georgia, United States, 30607
- University Cancer & Blood Center
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96819
- Kaiser Permanente Hawaii- Moanalua Medical Center
-
-
Idaho
-
Boise, Idaho, United States, 83706
- Saint Alphonsus Regional Medical Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
New York
-
East Setauket, New York, United States, 11733
- North Shore Hematology-Oncology Associates, PC
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Portland Medical Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37240
- Vanderbilt University
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Inova Schar Cancer Institute
-
-
Washington
-
Lacey, Washington, United States, 98503
- Providence Regional Cancer System
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Clinical Science Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive by an FDA-approved assay performed centrally. Patients must be ALK positive by local test prior to submitting tissue to the central lab. Randomization will occur after ALK positive confirmation is received from the central lab. Patients may have received up to 1 prior chemotherapy regimen for metastatic disease, which may also include maintenance therapy. Note that patients that have received adjuvant or neoadjuvant chemotherapy and developed metastatic disease within 6 months from the end of that therapy would be considered to have received 1 prior regimen for metastatic disease.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 2. (see Appendix A)
- Life expectancy of at least 12 weeks.
- Ability to swallow and retain oral medication.
Adequate organ system function, defined as follows:
- Absolute neutrophil count (ANC) ≥1.5 x 109/L
- Platelets ≥100 x 109/L
- Hemoglobin ≥9 g/dL (≥90 g/L) Note that transfusions are allowed to meet the required hemoglobin level
- Total bilirubin ≤1.5 times the upper limit of normal (ULN)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN if no liver involvement or ≤5 x ULN with liver involvement.
- Creatinine < 1.5 x ULN. If >1.5 x ULN, patient may still be eligible if calculated creatinine clearance >50 mL/min (0.83mL/s) as calculated by the Cockcroft-Gault method.
- Brain metastases allowed if asymptomatic at study baseline. Patients with untreated brain metastases must not be on corticosteroids. If patients have neurological symptoms or signs due to CNS metastases, patients need to complete whole brain radiation or focal treatment at least 14 days before start of study treatment and be asymptomatic on stable or decreasing doses of corticosteroids at baseline.
- Men with partners of childbearing potential willing to use adequate contraceptive measures during the study and for 90 days after the last dose of study medication.
- Women who are not of child-bearing potential, and women of child-bearing potential who agree to use adequate contraceptive measures during the study and for 90 days after the last dose of study medication, and who have a negative serum or urine pregnancy test within 1 week prior to initial trial treatment.
- Patients must be >18 years-of-age.
- Patients must have measurable disease per RECIST v. 1.1.
- Willingness and ability to comply with the trial and follow-up procedures.
- Ability to understand the nature of this trial and give written informed consent.
Note the following pertains to patients enrolled in France
In France, a subject will be eligible for inclusion in this study only affiliated to the French Social Security system, and currently benefit from the corresponding rights and cover.
Exclusion Criteria
- Patients that have previously received an ALK TKI or PD-1/PD-L1 therapy, and patients currently receiving cancer therapy (i.e., other targeted therapies, chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization).
- Use of an investigational drug within 21 days prior to the first dose of study drug. Note that to be eligible, any drug-related toxicity should have recovered to Grade 1 or less, with the exception of alopecia.
- Any chemotherapy within 4 weeks, or major surgery or radiotherapy within the last 14 days.
- Patients with primary CNS tumors and leptomeningeal disease are ineligible.
- Patients with a previous malignancy within the past 3 years (other than curatively treated basal cell carcinoma of the skin, in situ carcinoma of the cervix, or any cancer that is considered to be cured and have no impact on PFS and OS for the current NSCLC).
- Concomitant systemic use of anticancer herbal medications. These should be stopped prior to study entry.
Patients receiving
- strong CYP3A inhibitors (including, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, grapefruit, grapefruit juice)
- strong CYP3A inducers (including, but not limited to, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St. John's Wort)
- CYP3A substrates with narrow therapeutic window (including, but not limited to, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus).
- Women who are pregnant or breastfeeding.
- Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medications.
- Patients at risk for GI perforation.
Clinically significant cardiovascular disease including:
- QTcF interval >450 ms for men and >470 ms for women, symptomatic bradycardia <45 beats per minute or other significant ECG abnormalities in the investigator's opinion.
- Clinically uncontrolled hypertension in the investigator's opinion (e.g., blood pressure >160/100 mmHg; note that isolated elevated readings considered to not be indicative of uncontrolled hypertension are allowed).
The following within 6 months prior to Cycle 1 Day 1:
- Congestive heart failure (New York Heart Class III or IV).
- Arrhythmia or conduction abnormality requiring medication. Note: patients with atrial fibrillation/flutter controlled by medication and arrhythmias controlled by pacemakers are eligible.
- Severe/unstable angina, coronary artery/peripheral bypass graft, or myocardial infarction.
- Cerebrovascular accident or transient ischemia.
- Patients who are immunosuppressed (including known HIV infection), have a serious active infection at the time of treatment, have interstitial lung disease/pneumonitis, or have any serious underlying medical condition that would impair the ability of the patient to receive protocol treatment. Patients with controlled hepatitis C, in the investigator's opinion, are allowed. Patients with known hepatitis B must be HBeAg and HB viral DNA negative for enrollment. Note that, because of the high prevalence, all patients in the Asia-Pacific region (except Australia, New Zealand, and Japan) must be tested and, if HBsAg positive, must be HBeAg and HB viral DNA negative for enrollment.
- Known hypersensitivity to tartrazine, a dye used in the ensartinib 100 mg capsule.
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
- Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol or would impart excessive risk associated with study participation that would make it inappropriate for the patient to be enrolled.
Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
Note the following pertains to patients enrolled in France
- In France, a subject will not be eligible when under legal protection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: X-396 (ensartinib)
Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops
|
oral ALK inhibitor
|
ACTIVE_COMPARATOR: crizotinib
Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops
|
oral ALK inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival (PFS) as assessed by independent radiology review based on RECIST v. 1.1 criteria
Time Frame: 36 months
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival (OS)
Time Frame: 48 months
|
48 months
|
CNS response rate based on independent radiology review
Time Frame: 36 months
|
36 months
|
Time to CNS progression based on independent radiology review
Time Frame: 36 months
|
36 months
|
ORR based on independent radiology review
Time Frame: 36 months
|
36 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PFS based on investigator assessment
Time Frame: 36 months
|
36 months
|
ORR based on investigator assessment
Time Frame: 36 months
|
36 months
|
Time to response based on investigator assessment and independent radiology review
Time Frame: 36 months
|
36 months
|
Duration of Response based on investigator assessment and independent radiology review
Time Frame: 36 months
|
36 months
|
CNS response rate based on investigator assessment
Time Frame: 36 months
|
36 months
|
Time to CNS progression based on investigator assessment
Time Frame: 36 months
|
36 months
|
Patient reported time to deterioration (TTD) as measured by the EORTC C30/LC13 QoL questionnaire and Lung Cancer Symptom Scale (LCSS)
Time Frame: 36 months
|
36 months
|
Patient reported health-related quality of life (HRQoL) as measured by the EORTC C30/LC13 QoL questionnaire and LCSS
Time Frame: 36 months
|
36 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Ensartinib
- Crizotinib
Other Study ID Numbers
- X396-CLI-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on X-396 (ensartinib)
-
Xcovery Holding Company, LLCCompletedAdvanced Solid Tumors | Non-small Cell Lung CancerUnited States
-
Xcovery Holdings, Inc.CompletedBioequivalencyUnited States
-
Fudan UniversityBetta Pharmaceuticals Co., Ltd.UnknownNonsmall Cell Lung Cancer | Brain Metastases
-
Betta Pharmaceuticals Co., Ltd.Fudan UniversityUnknownBrain Metastases | Lung Cancer, Nonsmall CellChina
-
Betta Pharmaceuticals Co., Ltd.CompletedSolid Tumor | Non-Small Cell Lung Cancer MetastaticChina
-
Hebei Medical University Fourth HospitalRecruitingNon-small Cell Lung CancerChina
-
Betta Pharmaceuticals Co., Ltd.Completed
-
Xcovery Holding Company, LLCAvailableNon-Small Cell Lung Cancer | ALK Gene Rearrangement PositiveUnited States
-
Betta Pharmaceuticals Co., Ltd.RecruitingNon-small Cell Lung CancerChina
-
Li Zhang, MDRecruitingThe Diagnosis Was ALK Positive NSCLC | Second Generation ALK-TKI is Resistant | Efficacy of Ensatinib in This Subset of PatientsChina